What's It Going to Take to Lock Up Drug Company Execs?
Belief:
What if People Actually Treated Religion as Just a Metaphor (Like Trekkies and Secular Jews)?
Greta Christina
Corporate Accountability and WorkPlace:
Labor Against the War Shifting Sights to Afghanistan Occupation
Jane Slaughter
DrugReporter:
The War on Weed: Marijuana Is Basically Harmless -- The Monumentally Stupid Drug War Is Not
Jim Hightower
Environment:
20 Weird, Crazy Ideas for Helping the Earth
Food:
The War on Soy: Why the 'Miracle Food' May Be a Health Risk and Environmental Nightmare
Tara Lohan
Health and Wellness:
When Sex Hurts, and No One Can Tell You Why: The Mysterious Condition Called Vulvodynia
Carey Purcell
Immigration:
What Denying Unauthorized Immigrants Health Insurance Will Cost You
Media and Technology:
The Memory Scrub About Why Ft. Hood Happened Is Almost Complete ... If It Weren't for Archives
Mark Ames
Movie Mix:
The Yes Men: Pranksters Out to Fix the World
Mark Engler
Politics:
Just When You Thought It Was Safe: 3 Potential Obstacles to Health-Care Reform
Adele M. Stan
Reproductive Justice and Gender:
Why the New Breast Cancer Guidelines Are Racist
Devona Walker
Rights and Liberties:
Economic Crisis Is Getting Bloody -- Violent Deaths Are Now Following Evictions, Foreclosures and Job Losses
Nick Turse
Sex and Relationships:
Hot Mormon Muffins and Models for Jesus: What's With All the Sexy Christians?
Liz Langley
Take Action:
G-20 Meetings: Nothing Much Happened in the Suites, and There Was Too Much Punch in the Streets
Laura Flanders
Water:
Poseidon's Financial Shell Game: Why Is a Private Desalination Plant Asking for Public Money?
Peter Gleick
World:
The Obama Speech America Is Dying to Hear: "This Administration Ended, Rather Than Extended, Two Wars"
Tom Engelhardt
"Laws are like cobwebs, which may catch small flies, but let wasps and hornets break through." - Jonathan Swift
After reading "The Neurontin Legacy -- Marketing through Misinformation and Manipulation" in the January 8, 2009 issue of the New England Journal of Medicine, one may conclude that (1) America's prisons would be put to better use incarcerating drug company executives instead of pot smokers, and (2) society may need a return of public scorn via the pillory for those doctors who are essentially drug-company shills.
Drug-company corruption of American medicine is of course not news. What is news is that such corruption has become so egregious, so transparent, and so embarrassing that the New England Journal of Medicine, perhaps the most influential American medical journal, is now stating that "drastic action is essential to preserve the integrity of medical science and practice and to justify public trust."
Neurontin was approved by the Food and Drug Administration (FDA) in 1993 in doses of up to 1800 mg per day as adjunctive therapy for partial complex seizures. How did U.S. annual sales of Neurontin increase from $98 million in 1995 to nearly $3 billion in 2004? The answer is "off-label" marketing, in which Neurontin manufacturer Parke-Davis (a division of Warner-Lambert purchased by Pfizer in 2000) marketed Neurontin to doctors for uses not approved by the FDA (because doctors can legally prescribe drugs for uses not approved by the FDA).
While aggressive off-label marketing to doctors is standard among drug companies, it is routinely kept quiet. But thanks to a Parke-Davis whistle blower, we have first-hand evidence of off-label marketing -- and how the Neurontin financial bonanza was created.
In 1996, David Franklin, a young biologist, took a sales representative position for Parke-Davis. But shortly after beginning the job, Franklin grew concerned that he was participating in the illegal marketing of Neurontin. Franklin reports that a Parke-Davis executive informed him and his fellow sales reps:
"I want you out there every day selling Neurontin. . . .We all know Neurontin's not growing for adjunctive therapy, besides that's not where the money is. Pain management, now that's money. Monotherapy [for epilepsy], that's money. . . . We can't wait for [physicians] to ask, we need [to] get out there and tell them up front. Dinner programs, CME [continuing medical education] programs, consultantships all work great but don't forget the one-on-one. That's where we need to be, holding their hand and whispering in their ear, Neurontin for pain, Neurontin for monotherapy, Neurontin for bipolar, Neurontin for everything. I don't want to see a single patient coming off Neurontin before they've been up to at least 4800 mg/day. I don't want to hear that safety crap either, have you tried Neurontin, every one of you should take one just to see there is nothing, it's a great drug."
Franklin left Parke-Davis and filed suit (ultimately, United States of America ex rel. David Franklin vs. Pfizer, Inc., and Parke-Davis Division of Warner-Lambert Company) alleging that off-label marketing of Neurontin constituted false claims designed to elicit payments from the federal government. In 2004, Warner-Lambert resolved criminal charges and civil liabilities by agreeing to plead guilty and pay $430 million -- less than 15 percent of the $3 billion the drug company had grossed on Neurontin in 2004.
See more stories tagged with: health, drug companies, fda, pharma, neurontin, off-label prescriptions
Bruce E. Levine, Ph.D., is a clinical psychologist and author of Surviving America's Depression Epidemic: How to Find Morale, Energy, and Community in a World Gone Crazy (Chelsea Green, 2007).
Liked this story? Get top stories in your inbox each week from AlterNet! Sign up now »
You've chosen to turn comments off for the entire site. Would you like to turn them back on?
Support AlterNet
Do you value the information you're getting from AlterNet? Please show your support with a tax-deductible donation.
Feedback
Tell us how we're doing.